Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

被引：1

作者：

Khountham, Soun ^{[1
]}

Shindiapina, Polina ^{[1
]}

Mo, Xiaokui ^{[2
]}

Lachowiez, Curtis ^{[3
]}

Wiczer, Tracy ^{[4
]}

Mousa, Luay ^{[1
]}

Rogers, Kerry A. ^{[1
]}

Andritsos, Leslie A. ^{[1
]}

Woyach, Jennifer A. ^{[1
]}

Byrd, John C. ^{[1
]}

Spurgeon, Stephen E. ^{[3
]}

Awan, Farrukh T. ^{[5
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA

[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

[4] Ohio State Univ, Ctr Comprehens Canc, Dept Pharm, Columbus, OH 43210 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Div Hematol & Med Oncol, Dallas, TX 75390 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 03期

关键词：

ATRIAL-FIBRILLATION; OUTCOMES; THERAPY;

D O I：

10.1080/10428194.2020.1838508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：716 / 721

页数：6

共 50 条

[21] How I manage ibrutinib-refractory chronic lymphocytic leukemia
Woyach, Jennifer A.
BLOOD, 2017, 129 (10) : 1270 - 1274
[22] Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib
Bachireddy, Pavan
Wu, Catherine J.
CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1547 - 1549
[23] Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, Natalia L.
Burger, Jan A.
Wodarz, Dominik
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (38) : 13906 - 13911
[24] Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Stephan, Pierre
Bouherrou, Khaled
Guillermin, Yann
Michallet, Anne-Sophie
Grinberg-Bleyer, Yenkel
CELLS, 2024, 13 (17)
[25] Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
Hing, Zachary A.
Mantel, Rose
Beckwith, Kyle A.
Guinn, Daphne
Williams, Erich
Smith, Lisa L.
Williams, Katie
Johnson, Amy J.
Lehman, Amy M.
Byrd, John C.
Woyach, Jennifer A.
Lapalombella, Rosa
BLOOD, 2015, 125 (20) : 3128 - 3132
[26] Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
Hillmen, Peter
Xie, Jing
Yong, Alan S. M.
Waweru, Catherine
Sorof, Thuy Anh
Goyal, Ravi K.
Davis, Keith L.
EJHAEM, 2021, 2 (02): : 219 - 227
[27] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Rogers, Kerry A.
Thompson, Philip A.
Allan, John N.
Coleman, Morton
Sharman, Jeff P.
Cheson, Bruce D.
Jones, Daniel
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Patel, Priti
Wang, Min Hui
Kipps, Thomas J.
HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
[28] Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases
Santoro, Rita Carlotta
Falbo, Mariapia
Levato, Luciano
Iannaccaro, Piergiorgio
Prejano, Simona
BLOOD COAGULATION & FIBRINOLYSIS, 2021, 32 (02) : 159 - 161
[29] Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes
Rhodes, Joanna M.
Lore, Vincent A., III
Mato, Anthony R.
Chong, Elise A.
Barrientos, Jacqueline C.
Gerson, James N.
Barta, Stefan K.
Landsburg, Daniel J.
Nasta, Sunita Dwivedy
Svoboda, Jakub
Loren, Alison W.
Schuster, Stephen J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 438 - +
[30] Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients"
Visentin, Andrea
Trentin, Livio
HAEMATOLOGICA, 2022, 107 (06) : 1489 - 1490

← 1 2 3 4 5 →